home / stock / sbtx / sbtx short
Short Information | Silverback Therapeutics Inc. (NASDAQ:SBTX)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 301,333 |
Total Actual Volume | 3,906,565 |
Short Trends | |
---|---|
Cover Days | 19 |
Short Days | 0 |
No Change Days | 1 |
Averages | |
---|---|
Average Short Volume | 15,067 |
Average Short Percentage | 8.90% |
Is there a SBTX Short Squeeze or Breakout about to happen?
See the SBTX Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
11-08-2022 | $5.82 | $5.87 | $6.15 | $5.72 | 116,700 | 7,200 | 6.17% |
11-07-2022 | $6.05 | $5.81 | $6.135 | $5.8 | 158,815 | 3,771 | 2.37% |
11-04-2022 | $6.1 | $6.01 | $6.1 | $5.86 | 130,885 | 7,168 | 5.48% |
11-03-2022 | $6.2 | $6.06 | $6.41 | $6.05 | 94,203 | 3,257 | 3.46% |
11-02-2022 | $6.16 | $6.23 | $6.46 | $5.89 | 140,774 | 10,970 | 7.79% |
11-01-2022 | $6.27 | $6.15 | $6.32 | $6.13 | 47,771 | 4,648 | 9.73% |
10-31-2022 | $6.14 | $6.22 | $6.5 | $6.08 | 372,532 | 17,046 | 4.58% |
10-28-2022 | $5.82 | $6.14 | $6.15 | $5.63 | 206,823 | 13,656 | 6.6% |
10-27-2022 | $6.18 | $5.78 | $6.18 | $5.545 | 230,517 | 12,676 | 5.5% |
10-26-2022 | $6.12 | $6.14 | $6.4 | $6.08 | 290,154 | 13,145 | 4.53% |
10-25-2022 | $5.84 | $6.13 | $6.4 | $5.84 | 306,580 | 24,063 | 7.85% |
10-24-2022 | $5.75 | $5.83 | $5.97 | $5.51 | 198,243 | 8,404 | 4.24% |
10-21-2022 | $6.02 | $5.73 | $6.0299 | $5.45 | 187,348 | 20,175 | 10.77% |
10-20-2022 | $5.79 | $5.9 | $6.1201 | $5.75 | 595,079 | 42,524 | 7.15% |
10-19-2022 | $5.59 | $5.26 | $5.62 | $5.2 | 51,285 | 6,818 | 13.29% |
10-18-2022 | $5.35 | $5.62 | $5.73 | $5.35 | 456,062 | 25,720 | 5.64% |
10-17-2022 | $5.26 | $5.5 | $5.58 | $5.26 | 159,770 | 61,274 | 38.35% |
10-14-2022 | $5.11 | $5.24 | $5.24 | $5.04 | 55,583 | 11,045 | 19.87% |
10-13-2022 | $4.97 | $5.17 | $5.17 | $4.91 | 58,500 | 4,021 | 6.87% |
10-12-2022 | $5.24 | $5.03 | $5.245 | $4.96 | 48,941 | 3,752 | 7.67% |
News, Short Squeeze, Breakout and More Instantly...
Silverback Therapeutics Inc. Company Name:
SBTX Stock Symbol:
NASDAQ Market:
Response addresses all additional requests in FDA CRL, including positive data from a repeat dose PK/PD study of neffy under nasal allergen challenge (NAC) conditions, and updated testing that detected no measurable nitrosamine levels, conducted per August 2023 FDA Guidance Submission...
Preparing to submit response to the FDA’s CRL for neffy ® (epinephrine nasal spray) in Type I allergic reactions in early Q2 2024, following successful completion of neffy repeat dose nasal allergen challenge study and nitrosamine assessments, with ...
Significant unmet need with 80-90% of patients with current epinephrine Rx not using as directed, and only ~15% of diagnosed severe Type I allergy population with a current epinephrine prescription Multiple favorable attributes and potential best-in-class profile of neffy highlighted ...